2.2 Resistant Hypertension, Secondary Causes & Special Populations

Resistant Hypertension, Secondary Etiologies, and Clinical Emergencies

Resistant hypertension represents a high-risk phenotype associated with a significantly elevated risk of stroke, myocardial infarction, heart failure, and chronic kidney disease. Managing resistant hypertension requires the ambulatory care pharmacist to systematically rule out pseudoresistance, screen for secondary causes, discontinue interfering substances, and optimize pharmacotherapy based on landmark clinical trials.

---

Defining Resistant Hypertension

Clinical Definitions

• True Resistant Hypertension: Clinic blood pressure remains $\ge 130/80\text{ mmHg}$ despite documented adherence to three or more antihypertensive agents of different pharmacological classes at maximally tolerated doses, one of which must be a diuretic (typically a long-acting thiazide-like diuretic such as chlorthalidone or indapamide, or a loop diuretic in advanced CKD).
• Controlled Resistant Hypertension: Clinic blood pressure is $<130/80\text{ mmHg}$, but requires four or more antihypertensive medications to achieve control.
• Refractory Hypertension: Blood pressure remains uncontrolled ($\ge 130/80\text{ mmHg}$) despite adherence to five or more antihypertensive agents of different classes, including a long-acting thiazide-like diuretic and a mineralocorticoid receptor antagonist (MRA).

---

Apparent vs. True Resistance: Ruling Out Pseudoresistance

Before initiating additional fourth-line agents or conducting extensive diagnostic workups, clinicians must rule out pseudoresistance, which accounts for over 50% of apparent treatment failures:

1. White-Coat Effect / White-Coat Hypertension: Elevated office readings with normal out-of-office blood pressure. Confirmation via 24-hour ABPM (mean daytime BP $<130/80\text{ mmHg}$ or 24-hr mean $<125/75\text{ mmHg}$) or HBPM (7-day average $<130/80\text{ mmHg}$) is mandatory.
2. Medication Non-Adherence: Evaluate fill histories through pharmacy claims data, inspect pill bottles, utilize single-pill combination (SPC) regimens, and explore drug adverse effects or financial barriers.
3. Suboptimal Dosing or Inappropriate Regimens: Failure to use a long-acting diuretic (e.g., using low-dose HCTZ 12.5 mg in a patient with eGFR 35 instead of chlorthalidone or a loop diuretic like torsemide).
4. Inaccurate Blood Pressure Measurement Technique: Using a cuff that is too small relative to the patient's arm circumference falsely elevates systolic and diastolic readings by 5 to 15 mmHg. Failure to allow a 5-minute rest period or talking during measurement also causes significant artifactual elevations.

---

Secondary Etiologies of Hypertension

Secondary hypertension accounts for approximately 10% to 20% of resistant cases. Identification allows for targeted or curative interventions.

Drug-Induced and Exogenous Causes of Hypertension

Ambulatory care pharmacists must systematically review medication profiles for agents that elevate blood pressure:

• Nonsteroidal Anti-inflammatory Drugs (NSAIDs & COX-2 Inhibitors): Inhibit renal prostacyclin ($\text{PGI}_2$) and $\text{PGE}_2$, causing renal vasoconstriction, sodium/water retention, and blunting the efficacy of ACEi, ARBs, and diuretics (+3 to 6 mmHg).
• Systemic Corticosteroids: Promote mineralocorticoid receptor-mediated sodium and water retention.
• Oral Decongestants (Pseudoephedrine, Phenylephrine): Direct vascular $\alpha_1$-adrenergic receptor stimulation causing peripheral vasoconstriction.
• Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs - Venlafaxine, Duloxetine): Dose-dependent noradrenergic stimulation elevating systemic vascular resistance.
• Calcineurin Inhibitors (Cyclosporine, Tacrolimus): Induce renal vasoconstriction and impair nitric oxide release; DHP CCBs are the preferred antihypertensive agents for management.
• Vascular Endothelial Growth Factor (VEGF) Inhibitors (Bevacizumab, Sunitinib, Lenvatinib): Decrease endothelial nitric oxide production and increase peripheral resistance (+5 to 15 mmHg).
• Other Substances: Oral contraceptives containing high-dose estrogen, licorice (glycyrrhizin inhibits $11\beta\text{-HSD2}$, mimicking hyperaldosteronism), ADHD stimulants (amphetamines, methylphenidate), excessive alcohol consumption, and cocaine/illicit sympathomimetics.

---

Fourth-Line Pharmacotherapy for Resistant Hypertension

When true resistant hypertension persists despite a triple regimen of ACEi/ARB + DHP CCB + Long-acting Thiazide-like Diuretic at optimal doses, the clinician must select an evidence-based fourth-line agent.

+-----------------------------------------------------------------------------+
|                   FOURTH-LINE & ADJUNCTIVE DRUG CLASSES                     |
+-----------------------+-----------------------+-----------------------------+
| Drug Class & Agent    | Key Landmark Evidence | Clinical Considerations     |
+-----------------------+-----------------------+-----------------------------+
| Mineralocorticoid     | PATHWAY-2 Trial       | Drug of choice for 4th-line |
| Receptor Antagonist:  | (Superior to          | therapy. Requires eGFR >= 30|
| Spironolactone        | doxazosin, bisoprolol,| and K+ < 4.5-5.0 mEq/L.     |
| (25-50 mg daily)      | and placebo)          | Gynecomastia risk (non-sel).|
+-----------------------+-----------------------+-----------------------------+
| Selective MRA:        | Alternative when      | Highly selective; no        |
| Eplerenone            | spironolactone causes | anti-androgenic side effects|
| (50-100 mg daily)     | gynecomastia/mastodynia| Less potent than spirono.   |
+-----------------------+-----------------------+-----------------------------+
| Vasodilating          | Preferred over        | Carvedilol (alpha-1 + beta) |
| Beta-Blockers:        | non-vasodilating BBs  | Nebivolol (beta-1 + NO).    |
| Carvedilol, Nebivolol | in metabolic syndrome | No adverse metabolic profile|
+-----------------------+-----------------------+-----------------------------+
| Central Alpha-2       | Lowers sympathetic   | High sedation, dry mouth,   |
| Agonists: Clonidine,  | outflow               | severe REBOUND HYPERTENSION |
| Guanfacine            |                       | if stopped abruptly.        |
+-----------------------+-----------------------+-----------------------------+
| Direct Vasodilators:  | Refractory cases only | MUST combine with BB (blunt |
| Hydralazine,          |                       | reflex tachycardia) and     |
| Minoxidil             |                       | loop diuretic (blunt edema).|
+-----------------------+-----------------------+-----------------------------+

The PATHWAY-2 Evidence

The PATHWAY-2 trial established Spironolactone (25–50 mg once daily) as the most effective fourth-line add-on agent for resistant hypertension, producing significantly greater systolic BP reductions ($-8.7\text{ mmHg}$ vs. placebo) compared to doxazosin ($-4.0\text{ mmHg}$) or bisoprolol ($-4.5\text{ mmHg}$). The pathophysiological mechanism in most resistant hypertension is occult sodium retention and subclinical volume expansion.

• Safety Monitoring Prerequisites for MRAs: Baseline eGFR must be $\ge 30\text{ mL/min}/1.73\text{m}^2$ and baseline serum potassium must be $<5.0\text{ mEq/L}$ (ideally $<4.5\text{ mEq/L}$). Serum potassium and creatinine must be re-evaluated at 1 to 2 weeks and 4 weeks after initiation.
• Alternative Agents: If spironolactone causes endocrine adverse effects (gynecomastia, breast pain, or menstrual irregularities due to non-selective progesterone/androgen receptor binding), switch to Eplerenone (50–100 mg daily).

---

Special Populations: Pregnancy & Demographic Considerations

Hypertension in Pregnancy

• Definitions: Chronic hypertension (present before pregnancy or diagnosed before 20 weeks gestation), Gestational hypertension (new onset after 20 weeks without proteinuria), and Preeclampsia (new-onset hypertension after 20 weeks with proteinuria [uACR $\ge 300\text{ mg/g}$] or end-organ dysfunction).
• Therapeutic BP Target: Blood pressure goal in pregnancy is typically 110–135 / 85 mmHg to prevent severe maternal cardiovascular complications while maintaining adequate uteroplacental perfusion.
• Preferred Safe First-Line Agents:
  1. Labetalol: Oral 100–400 mg twice to three times daily (preferred initial agent; balanced alpha/beta-blockade).
  2. Nifedipine ER: Oral 30–90 mg once daily (long-acting DHP CCB; safe and effective).
  3. Methyldopa: Oral 250–500 mg two to three times daily (long safety record, though limited by sedation, lethargy, and hepatic transaminase elevations).
• Strictly Contraindicated Antihypertensives in Pregnancy:
  • ACE Inhibitors, ARBs, and ARNIs: Teratogenic (Black Box Warning). Cause fetal renal dysgenesis, oligohydramnios, pulmonary hypoplasia, skull ossification defects, and intrauterine fetal demise.
  • Direct Renin Inhibitors (Aliskiren) and MRAs (Spironolactone): Contraindicated due to risk of fetotoxicity and anti-androgenic effects on the developing male fetus.
  • Nitroprusside: Contraindicated due to risk of fetal cyanide poisoning.

Black Patient Considerations

• Black adults have a higher prevalence of hypertension, earlier disease onset, and higher rates of stroke and end-stage kidney disease. Pathophysiologically, this population frequently exhibits low plasma renin activity.
• First-Line Selection: In the absence of CKD with albuminuria or heart failure, initial monotherapy should prioritize a DHP Calcium Channel Blocker (e.g., Amlodipine) or a Thiazide-like Diuretic (e.g., Chlorthalidone) over ACE inhibitors or ARBs (as demonstrated in the ALLHAT trial, which showed a 40% higher stroke rate and 19% higher CVD event rate with ACE inhibitor monotherapy compared to CCB/thiazide in Black patients).
• Combination Therapy: When Stage 2 hypertension requires dual therapy, combining an ACEi or ARB with a CCB or thiazide produces potent, additive BP lowering and restores renal/vascular protection.

---

Hypertensive Crises: Hypertensive Urgency vs. Emergency

A hypertensive crisis is defined as a severe acute elevation in blood pressure, typically systolic $\text{BP} >180\text{ mmHg}$ and/or diastolic $\text{BP} >120\text{ mmHg}$.

1. Hypertensive Emergency (With Acute Target Organ Damage)

• Definition: Severe BP elevation accompanied by acute, progressive end-organ dysfunction: acute aortic dissection, acute coronary syndrome / myocardial infarction, acute pulmonary edema with heart failure, acute ischemic stroke, intracerebral hemorrhage, hypertensive encephalopathy, acute renal failure, eclampsia/preeclampsia, or microangiopathic hemolytic anemia.
• Management Site: Intensive Care Unit (ICU) with continuous arterial line BP monitoring.
• Standard BP Lowering Rate Target: Reduce systolic BP by no more than 20% to 25% within the first hour; if hemodynamically stable, lower to $160/100\text{ mmHg}$ over the next 2 to 6 hours, and carefully normalize over the subsequent 24 to 48 hours. Overly rapid reduction risks cerebral, coronary, or renal hypoperfusion and ischemic infarction.
• Critical Exceptions to the Standard Reduction Rate:
  • Acute Aortic Dissection: Rapidly lower SBP to $<120\text{ mmHg}$ and heart rate to $<60\text{ bpm}$ within 20 minutes. An IV beta-blocker (e.g., esmolol or labetalol) must precede or accompany any vasodilator (e.g., nicardipine, nitroprusside) to prevent reflex tachycardia and increased aortic shear stress ($\text{d}P/\text{d}t$).
  • Acute Ischemic Stroke: For patients eligible for IV thrombolytic therapy (alteplase or tenecteplase), blood pressure must be carefully reduced to $<185/110\text{ mmHg}$ prior to thrombolysis and maintained $<180/105\text{ mmHg}$ for at least 24 hours post-infusion.
• First-Line IV Pharmacotherapy:
  • Labetalol: Combined $\alpha_1$- and non-selective $\beta$-blocker (7:1 IV ratio). Avoid in severe bradycardia, decompensated heart failure, or severe reactive airway disease.
  • Nicardipine: Dihydropyridine CCB; titratable IV infusion (5–15 mg/hr). Highly predictable and safe.
  • Clevidipine: Ultra-short-acting DHP CCB in a lipid emulsion, metabolized by blood/tissue esterases (half-life 1–2 minutes). Contraindicated in severe egg or soy allergies and lipid metabolism disorders.
  • Esmolol: Ultra-short-acting $\beta_1$-selective blocker (half-life 9 minutes); ideal for aortic dissection.
  • Sodium Nitroprusside: Direct NO donor; potent arteriolar and venous dilator. Carries high risk of cyanide and thiocyanate toxicity, especially with prolonged infusions ($>48\text{ hours}$), high doses ($>2\text{ mcg/kg/min}$), or renal/hepatic impairment.

2. Hypertensive Urgency (Without Acute Target Organ Damage)

• Definition: Severe BP elevation ($>180/>120\text{ mmHg}$) in an asymptomatic or minimally symptomatic patient (mild headache, anxiety) without evidence of acute end-organ damage.
• Management: Outpatient setting using oral antihypertensive agents. Rapid acute BP lowering in the ED is not indicated and may be harmful. Management involves reinstituting non-adherent maintenance medications, increasing maintenance doses, or adding an oral first-line agent (e.g., amlodipine, captopril, clonidine, or labetalol) with outpatient follow-up arranged within 24 to 72 hours.